Trial Profile

LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxychloroquine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms LIMIT; LIMIT Melanoma

11 Sep 2026 Planned primary completion date changed from 31 Jul 2026 to 13 Nov 2026.
16 Jun 2026 Planned End Date changed from 6 Jan 2027 to 12 May 2027.
16 Jun 2026 Planned primary completion date changed from 6 Jan 2027 to 31 Jul 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com